Common use of Agreement Preamble Clause in Contracts

Agreement Preamble. Alliance Manager 3.1 Anti-Corruption Laws 12.7(a)(i) Audited Party 9.10(b)(i) Auditing Party 9.10(b)(i) Breach Notification 15.2(b)(i) BTC Data Package 1.65 Claims 13.1 Clinical Supply Agreement 7.3(b) CMO 7.2 Commercial Supply Agreement 7.3(c) Commercialization Milestone Event 9.4 Commercialization Milestone Payment 9.4 Commitments Log 4.1 Confidentiality Agreement 17.11 Continuing Technology Transfer 4.1 Disclosing Party 1.21 Dispute 17.5(a) DMF 6.3 DOJ 16.2(a) Excluded Claim 1.1(e) Execution Date Preamble Executive Officers 17.5(a) Executive Sponsors 3.2(f) Existing Regulatory Materials 12.2(s) Ex-Territory Infringement 14.4(a) First BLA 6.2(b) FTC 16.2(b) Global Brand Elements 8.3(c) HSR Filing 16.1(a) ICH Guidelines 1.37 Indemnified Party 13.3 Indemnifying Party 13.3 Initial Technology Transfer 4.1 Jazz Preamble Jazz Collaboration IP 14.1(a) Jazz Collaboration Patent Rights 14.3(d) Jazz Competing Product 1.1(a) Jazz Indemnitee(s) 13.2 Jazz Publication 11.1(b) Joint Collaboration IP 14.1(a) Joint Patent Rights 14.1(d) JSC 3.2(a) License 2.1(b) Losses 13.1 Manufacturing Technology Transfer 7.2 Manufacturing Technology Transfer Plan 7.2 Manufacturing Transition Date 7.3(a) Manufacturing Working Group 3.2(g)(ii) Negotiation Period 2.8 Notice of Dispute 17.5(a) Offered Rights 2.8 Parties Preamble Party Preamble Patent Liaison 14.2 [*** ***] Post-Approval Commitments 6.7(b) PPQ 7.4(a) Product Infringement 14.4(a) Product Marks 14.9(a) Public Official 12.7(d) Publication 11.1(c) Quality Technical Agreement 7.3(d) Receiving Party 1.21 Regulatory Milestone Event 9.3 Regulatory Milestone Payment 9.3 Regulatory Working Group 3.2(g)(iii) Request Period 2.8 Review Period 11.1(b) Royalty Floor 9.6(c)(iii) Royalty Term 9.6(b) Safety Working Group 3.2(g)(iv) SDEA Agreement 6.4 SEC 11.3(c) Second Payment 9.1(b) Second Payment Due Date 9.1(b) Second Request 16.1(b) Securities Regulators 11.3(c) Technology Transfer 4.1 Term 15.1 Territory Development Plan 5.4 Upfront Payment 9.1(a) Western Europe 1.60 Working Group 3.2(g)(i) [*** ***] Zanidatamab 1.50 Zymeworks Preamble Zymeworks Collaboration IP 14.1(a) Zymeworks Competing Product 1.1(b) Zymeworks Development Plan 5.2(a) Zymeworks Domain Names 14.9(b)(v) Zymeworks Indemnitee(s) 13.1 Zymeworks Manufacturing IP 7.2 Zymeworks Platform Patents 1.79 Zymeworks Publication 11.1(c)

Agreement Preamble. Alliance Manager Annual Royalty Cap 4.5.1(b) BBA LIBOR 1.47 “[***]” Preamble “[***]” Indemnitees 10.2 Claim 10.1 Clinical Collaboration Product Supply 3.3.5 Combination Product 1.53 Commercial Period 3.1 Anti-Corruption Laws 12.7(a)(i) Audited Party 9.10(b)(i) Auditing Party 9.10(b)(i) Breach Notification 15.2(b)(i) BTC Data Package 1.65 Claims 13.1 Clinical Supply Agreement 7.3(b) CMO 7.2 Commercial Period Milestone Event 4.4.1 Commercial Period Milestone Payment 4.4.1 Commercial Supply Agreement 7.3(c3.3.6(b) Commercialization Milestone Event 9.4 Commercialization Milestone Payment 9.4 Commitments Log 4.1 Confidentiality Agreement 17.11 Continuing Technology Transfer 4.1 Disclosing Party 1.21 Dispute 17.5(a) DMF 6.3 DOJ 16.2(a) Excluded Claim 1.1(e) Execution Date Preamble Executive Officers 17.5(a) Executive Sponsors 3.2(f) Existing Regulatory Materials 12.2(s) Ex-Territory Infringement 14.4(a) First BLA 6.2(b) FTC 16.2(b) Global Brand Elements 8.3(c) HSR Filing 16.1(a) ICH Guidelines 1.37 Indemnified Party 13.3 Indemnifying Party 13.3 Initial Technology Transfer 4.1 Jazz Preamble Jazz Collaboration IP 14.1(a) Jazz Collaboration Patent Rights 14.3(d) Jazz Competing Product 1.1(a) Jazz Indemnitee(s) 13.2 Jazz Publication 11.1(b) Joint Collaboration IP 14.1(a) Joint Patent Rights 14.1(d) JSC 3.2(a) License 2.1(b) Losses 13.1 Manufacturing Technology Transfer 7.2 Manufacturing Technology Transfer Plan 7.2 Manufacturing Transition Date 7.3(a) Manufacturing Working Group 3.2(g)(ii) Negotiation Period 2.8 Notice of Dispute 17.5(a) Offered Rights 2.8 Parties Preamble Party Preamble Patent Liaison 14.2 “[*** *]” Preamble Effective Date Preamble Failure of PART B Deliverables 2.3.2(b) Field Expansion 2.5 FCPA 9.2.15 Gross Sales 1.53 Indemnified Party 10.3 Indemnifying Party 10.3 Infringement 7.2.1 Infringement Notice 7.2.1 Insolvency Event 8.2.4 NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***] Post]” IN PLACE OF THE REDACTED LANGUAGE. Intec Pharma Preamble Intec Pharma Indemnitees 10.1 Intec Pharma-Approval Commitments 6.7(bOwned Technology 9.2.12 License Fee 4.2 Losses 10.1 Manufacturing Know-How 3.3.7 Option 2.4.2 Option Exercise Date 2.4.2 Option Exercise Notice 2.4.2 Option Exercise Period 2.4.1 PART A Deliverables 2.3.2(a) PPQ 7.4(aPART B Deliverables 2.3.2(b) Product Infringement 14.4(aPART B Election Notice 2.3.2(a) Product Marks 14.9(aParty/Parties Preamble Patent Coordinator 6.5 Phase 1 Clinical Trial Materials 2.3.2(b) Public Official 12.7(dPhase 1 Materials Acceptance Date 2.3.2(b) Publication 11.1(c) Quality Technical Agreement 7.3(d) Receiving Party 1.21 Regulatory Pre-Commercialization Collaboration Notice 3.3.2 Pre-Commercialization Plan 3.3.2 Research Period 2.1 Research Period Milestone Event 9.3 Regulatory 4.3.1 Research Period Milestone Payment 9.3 Regulatory Working Group 3.2(g)(iii) Request Period 2.8 Review Period 11.1(b) Royalty Floor 9.6(c)(iii) Royalty Term 9.6(b) Safety Working Group 3.2(g)(iv) SDEA Agreement 6.4 SEC 11.3(c) Second Payment 9.1(b) Second Payment Due Date 9.1(b) Second Request 16.1(b) Securities Regulators 11.3(c) 4.3.1 Sunshine Act 9.2.15 Technology Transfer 4.1 3.3.7 Term 15.1 Territory Development Plan 5.4 Upfront Payment 9.1(a) Western Europe 1.60 Working Group 3.2(g)(i) [*** ***] Zanidatamab 1.50 Zymeworks Preamble Zymeworks Collaboration IP 14.1(a) Zymeworks Competing Product 1.1(b) Zymeworks Development Plan 5.2(a) Zymeworks Domain Names 14.9(b)(v) Zymeworks Indemnitee(s) 13.1 Zymeworks Manufacturing IP 7.2 Zymeworks Platform Patents 1.79 Zymeworks Publication 11.1(c)8.1 U.S. GAAP 1.53 UK Bribery Act 9.2.15

Agreement Preamble. Alliance Manager Annual Royalty Cap 4.5.1(b) BBA LIBOR 1.47 Biogen Preamble Biogen Indemnitees 10.2 Claim 10.1 Clinical Collaboration Product Supply 3.3.5 Combination Product 1.53 Commercial Period 3.1 Anti-Corruption Laws 12.7(a)(i) Audited Party 9.10(b)(i) Auditing Party 9.10(b)(i) Breach Notification 15.2(b)(i) BTC Data Package 1.65 Claims 13.1 Clinical Supply Agreement 7.3(b) CMO 7.2 Commercial Period Milestone Event 4.4.1 Commercial Period Milestone Payment 4.4.1 Commercial Supply Agreement 7.3(c3.3.6(b) Commercialization Milestone Event 9.4 Commercialization Milestone Payment 9.4 Commitments Log 4.1 Confidentiality Agreement 17.11 Continuing Technology Transfer 4.1 Disclosing Party 1.21 Dispute 17.5(a) DMF 6.3 DOJ 16.2(a) Excluded Claim 1.1(e) Execution Date Preamble Executive Officers 17.5(a) Executive Sponsors 3.2(f) Existing Regulatory Materials 12.2(s) Ex-Territory Infringement 14.4(a) First BLA 6.2(b) FTC 16.2(b) Global Brand Elements 8.3(c) HSR Filing 16.1(a) ICH Guidelines 1.37 Indemnified Party 13.3 Indemnifying Party 13.3 Initial Technology Transfer 4.1 Jazz Preamble Jazz Collaboration IP 14.1(a) Jazz Collaboration Patent Rights 14.3(d) Jazz Competing Product 1.1(a) Jazz Indemnitee(s) 13.2 Jazz Publication 11.1(b) Joint Collaboration IP 14.1(a) Joint Patent Rights 14.1(d) JSC 3.2(a) License 2.1(b) Losses 13.1 Manufacturing Technology Transfer 7.2 Manufacturing Technology Transfer Plan 7.2 Manufacturing Transition Date 7.3(a) Manufacturing Working Group 3.2(g)(ii) Negotiation Period 2.8 Notice of Dispute 17.5(a) Offered Rights 2.8 Parties Preamble Party Preamble Patent Liaison 14.2 “[*** *]” Preamble Effective Date Preamble Failure of PART B Deliverables 2.3.2(b) Field Expansion 2.5 FCPA 9.2.15 Gross Sales 1.53 Indemnified Party 10.3 Indemnifying Party 10.3 Infringement 7.2.1 Infringement Notice 7.2.1 Insolvency Event 8.2.4 NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***] Post]” IN PLACE OF THE REDACTED LANGUAGE. Intec Pharma Preamble Intec Pharma Indemnitees 10.1 Intec Pharma-Approval Commitments 6.7(bOwned Technology 9.2.12 License Fee 4.2 Losses 10.1 Manufacturing Know-How 3.3.7 Option 2.4.2 Option Exercise Date 2.4.2 Option Exercise Notice 2.4.2 Option Exercise Period 2.4.1 PART A Deliverables 2.3.2(a) PPQ 7.4(aPART B Deliverables 2.3.2(b) Product Infringement 14.4(aPART B Election Notice 2.3.2(a) Product Marks 14.9(aParty/Parties Preamble Patent Coordinator 6.5 Phase 1 Clinical Trial Materials 2.3.2(b) Public Official 12.7(dPhase 1 Materials Acceptance Date 2.3.2(b) Publication 11.1(c) Quality Technical Agreement 7.3(d) Receiving Party 1.21 Regulatory Pre-Commercialization Collaboration Notice 3.3.2 Pre-Commercialization Plan 3.3.2 Research Period 2.1 Research Period Milestone Event 9.3 Regulatory 4.3.1 Research Period Milestone Payment 9.3 Regulatory Working Group 3.2(g)(iii) Request Period 2.8 Review Period 11.1(b) Royalty Floor 9.6(c)(iii) Royalty Term 9.6(b) Safety Working Group 3.2(g)(iv) SDEA Agreement 6.4 SEC 11.3(c) Second Payment 9.1(b) Second Payment Due Date 9.1(b) Second Request 16.1(b) Securities Regulators 11.3(c) 4.3.1 Sunshine Act 9.2.15 Technology Transfer 4.1 3.3.7 Term 15.1 Territory Development Plan 5.4 Upfront Payment 9.1(a) Western Europe 1.60 Working Group 3.2(g)(i) [*** ***] Zanidatamab 1.50 Zymeworks Preamble Zymeworks Collaboration IP 14.1(a) Zymeworks Competing Product 1.1(b) Zymeworks Development Plan 5.2(a) Zymeworks Domain Names 14.9(b)(v) Zymeworks Indemnitee(s) 13.1 Zymeworks Manufacturing IP 7.2 Zymeworks Platform Patents 1.79 Zymeworks Publication 11.1(c)8.1 U.S. GAAP 1.53 UK Bribery Act 9.2.15

Agreement Preamble. Alliance Manager 3.1 Anti-Corruption Laws 12.7(a)(i) 2.1 Arising Core Adaptimmune Patents 9.8.3 Arising Core Universal Cells Patents 9.8.4 Astellas Preamble Audited Party 9.10(b)(i11.6 Base Product 1.69 [***] 1.113 Burdened Technology 3.3.3(a) Auditing Burdened Technology Clearance 3.3.3(b) Burdened Technology Limitations 3.3.3(a) Ceasing Party 9.10(b)(i) Breach Notification 15.2(b)(i) BTC Data Package 1.65 Claims 13.1 Clinical Supply Agreement 7.3(b) CMO 7.2 Commercial Supply Agreement 7.3(c) 13.5.3 Co-Commercialization Milestone Event 9.4 Commercialization Milestone Payment 9.4 Commitments Log 4.1 Confidentiality Agreement 17.11 Continuing Technology Transfer 4.1 Disclosing Party 1.21 Dispute 17.5(a) DMF 6.3 DOJ 16.2(a) Excluded Claim 1.1(e) Execution Date Preamble Executive Officers 17.5(a) Executive Sponsors 3.2(f) Existing Regulatory Materials 12.2(s) ExBudget 6.2 Co-Territory Infringement 14.4(a) First BLA 6.2(b) FTC 16.2(b) Global Brand Elements 8.3(c) HSR Filing 16.1(a) ICH Guidelines 1.37 Indemnified Party 13.3 Indemnifying Party 13.3 Initial Technology Transfer 4.1 Jazz Preamble Jazz Development Budget 5.1 Collaboration IP 14.1(a) Jazz Collaboration Patent Rights 14.3(d) Jazz Competing Product 1.1(a) Jazz Indemnitee(s) 13.2 Jazz Publication 11.1(b) Joint Collaboration IP 14.1(a) Joint Patent Rights 14.1(d9.8.5 Collaboration Profit-Share Target 4.10.2 Collaboration Research Plan Budget 4.1 Collaboration Research Program Opt-Out Notice 4.11 Collaboration Substitution Target 4.6.1 Combination Product 1.69 Co-Medical Affairs Plan 2.5.2(a) Commercialization Agreement 6.3 Competitive Activities 10.3 Continuing Development and Commercialization Notice 4.10.1 Continuing Party 13.5.3 Contributed Technology 3.5 Contributed Technology Dispute Notice 3.5 Contributed Technology Notice 3.5 Defending Party 9.10.1 Disputed Contributed Technology 3.5 Early Continuation Notice 4.11 Effective Date Preamble Elected Unilateral Adaptimmune Product License 9.2.1 Elected Unilateral Adaptimmune Target 9.2.1 Elected Universal Cells Program Product License 9.2.2 Elected Universal Cells Program Target 9.2.2 Enforcing Party 9.9.7 Excluded Target Clearance 3.3.1 Executive Resolution Matters 2.2.4(b) Existing Agreement Preamble First Collaboration Target Nomination Date 3.2.1 Indemnitee 16.3 Indemnitor 16.3 Indirect Taxes 11.9.2 JCC 2.7.1 JDC 2.4.1 JFC 2.6.1 JMAC 2.5.1 JRC 2.3.1 JSC 3.2(a) License 2.1(b) 2.2.1 Lapsed Target 4.10.4 Licensed Unilateral Universal Cells Product Patent 1.104 Losses 13.1 Manufacturing Technology Transfer 7.2 Manufacturing Technology Transfer Plan 7.2 Manufacturing Transition Date 7.3(a) Manufacturing Working Group 3.2(g)(ii) Negotiation Period 2.8 16.1 Non-Excluded Target 1.44 Non-Publishing Party 12.6.3 Opt-Out Notice of Dispute 17.5(a) Offered Rights 2.8 5.3 Other Component 1.69 Parties Preamble Party Preamble Patent Liaison 14.2 [*** ***] Post-Approval Commitments 6.7(b) PPQ 7.4(a) Product Infringement 14.4(a) Product Marks 14.9(a) Public Official 12.7(d) Publication 11.1(c) Quality Technical Agreement 7.3(d) Receiving Phase 1 Data Availability Date 4.10.1 Phase 1 Success Criteria 4.1 Publishing Party 1.21 Regulatory Milestone Event 9.3 Regulatory Milestone Payment 9.3 Regulatory Working Group 3.2(g)(iii) Request Period 2.8 Review Period 11.1(b12.6.3 Qualifying Adaptimmune Change of Control 17.2.3 Qualifying Adaptimmune CoC Notice 17.2.3(a) Royalty Floor 9.6(c)(iiiConversion Payments 17.2.3(f) Royalty Rules 14.2.1 Sale Transaction 17.2.1 Second Collaboration Target Nomination Date 3.2.1 Selling Party 1.69 Target Substitution Right 4.6.1 Term 9.6(b13.1 Third Collaboration Target Nomination Date 3.2.1 Third Party Acquirer 17.2.2(a) Safety Working Group 3.2(g)(ivThird Party Claim 16.1 Third Party License 11.4.6(b) SDEA Agreement 6.4 SEC 11.3(cUnilateral Adaptimmune Product Elected License Notice 9.2.1 Unilateral Adaptimmune Product-Specific Collaboration Joint Patent Rights 9.9.5(d) Second Payment 9.1(bUnilateral Adaptimmune Product-Specific Patents 9.8.6 Unilateral Adaptimmune Target 4.10.3(b) Second Payment Due Date 9.1(bUnilateral Universal Cells Product-Specific Patents 9.8.7 Universal Cells Preamble Universal Cells Acquiree 17.2.2(a) Second Request 16.1(bUniversal Cells Acquisition 17.2.2(a) Securities Regulators 11.3(c) Technology Transfer 4.1 Term 15.1 Territory Development Plan 5.4 Upfront Payment 9.1(a) Western Europe 1.60 Working Group 3.2(g)(i) [*** ***] Zanidatamab 1.50 Zymeworks Preamble Zymeworks Collaboration IP 14.1(a) Zymeworks Competing Universal Cells Background Patents 9.8.2 Universal Cells Election Period 9.2.1 Universal Cells Impediment 3.5 Universal Cells Indemnified Parties 16.1 Universal Cells Program 8.2 Universal Cells Program Product 1.1(b) Zymeworks Development Plan 5.2(a) Zymeworks Domain Names 14.9(b)(v) Zymeworks Indemnitee(s) 13.1 Zymeworks Manufacturing IP 7.2 Zymeworks Platform Patents 1.79 Zymeworks Publication 11.1(c)Elected License Notice 9.2.2 Universal Cells Research Activities 8.1 Universal Cells Substitution Target 4.6.1 Withholding Party 11.9.1